Sibutramine: A banned innocent antiobesity drug

Abstract

Obesity is a major public health problem. In spite of many
dietaries and lifestyle suggestions, more than 80% of affected
cases cannot achieve weight loss.[1] Sibutramine is a combined
norepinephrine and serotonin reuptake inhibitor attribute
to the enhancement of satiety and decrease in caloric intake
instead of anorectic action. Sibutramine was approved in
1998 and has been widely evaluated in several trials, which
take place between 16 and 52 weeks